These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome. Piña-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J. Epilepsy Behav; 2017 Aug; 73():46-50. PubMed ID: 28609734 [Abstract] [Full Text] [Related]
3. The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis. Reaven NL, Funk SE, Lyons PD, Story TJ. Epilepsy Behav; 2019 Apr; 93():65-72. PubMed ID: 30831405 [Abstract] [Full Text] [Related]
4. The burden of illness in Lennox-Gastaut syndrome: a systematic literature review. Strzelczyk A, Zuberi SM, Striano P, Rosenow F, Schubert-Bast S. Orphanet J Rare Dis; 2023 Mar 01; 18(1):42. PubMed ID: 36859290 [Abstract] [Full Text] [Related]
8. The High Direct Medical Costs of Prader-Willi Syndrome. Shoffstall AJ, Gaebler JA, Kreher NC, Niecko T, Douglas D, Strong TV, Miller JL, Stafford DE, Butler MG. J Pediatr; 2016 Aug 01; 175():137-43. PubMed ID: 27283463 [Abstract] [Full Text] [Related]
10. Applying the ILAE diagnostic criteria for Lennox-Gastaut syndrome in the real-world setting: A multicenter retrospective cohort study. Nightscales R, Chen Z, Barnard S, Auvrez C, Tao G, Sivathamboo S, Bennett C, Rychkova M, D'Souza W, Berkovic SF, Nicolo JP, O'Brien TJ, Perucca P, Scheffer IE, Kwan P. Epilepsia Open; 2024 Apr 01; 9(2):602-612. PubMed ID: 38135919 [Abstract] [Full Text] [Related]
11. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations. Klein K, Soliman AM, Bonafede M, Nelson JK, Grubb E. J Manag Care Spec Pharm; 2019 Jul 01; 25(7):836-846. PubMed ID: 31232203 [Abstract] [Full Text] [Related]
12. Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study. Chin RFM, Pickrell WO, Guelfucci F, Martin M, Holland R. Seizure; 2021 Oct 01; 91():159-166. PubMed ID: 34161904 [Abstract] [Full Text] [Related]
14. Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome. François C, Stern JM, Ogbonnaya A, Lokhandwala T, Landsman-Blumberg P, Duhig A, Shen V, Tan R. J Mark Access Health Policy; 2017 Oct 01; 5(1):1318691. PubMed ID: 28740620 [Abstract] [Full Text] [Related]
15. Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance. Ivanova JI, Birnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA. Am J Manag Care; 2011 Aug 01; 17(8):e314-23. PubMed ID: 21851139 [Abstract] [Full Text] [Related]
16. Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review. Samanta D. Epilepsy Behav; 2021 Jan 01; 114(Pt A):107612. PubMed ID: 33243685 [Abstract] [Full Text] [Related]
17. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Benedict A, Verdian L, Maclaine G. Pharmacoeconomics; 2010 Jan 01; 28(3):185-99. PubMed ID: 20151724 [Abstract] [Full Text] [Related]